The development of SLU-PP-332 (\u201cexercise in a bottle\u201d) was a real pharmacological breakthrough. It paved the way for research and future clinical applications that simply weren\u2019t possible before \u2014 and it definitely wasn\u2019t easy.\u00a0<\/span><\/p>\n CellPeptides is an EU-based research chemical company who tries to live up to that exciting legacy. We provide pharmacological-grade SLU-PP-332 with the potential to form the basis for brand new discoveries.\u00a0<\/span><\/p>\n With us, you get:<\/span><\/p>\n We handle the reliability (our SLU-PP-332 is synthesized in an EU-based WHO\/GMP and ISO 9001:2015 certified lab), so you get the compound you need to contribute to the future of science. Every time.<\/span><\/p>\n You wanted a look under the hood, and you\u2019ll get one. SLU-PP-332 is a small molecule synthetic compound (not a peptide) specifically designed to act on estrogen-related receptors. A team from St Louis University led the way \u2014 hence the \u201cSLU\u201d in the name.<\/span><\/p>\n Three of these receptors exist, and SLU-PP-332 targets them all. Switching them on creates a state usually induced when people are under physical stress, AKA when they\u2019re engaged in endurance exercise. That, in turn, has some interesting knock-on effects. Cells make more mitochondria. Muscles burn fat for energy \u2014 and they\u2019re optimized for endurance.\u00a0<\/span><\/p>\n Basically? SLU-PP-332 makes muscles more metabolically efficient. It makes them more resistant to fatigue. It creates an environment usually only available to people who\u2019ve been subjecting themselves to strenuous resistance training. That? It might make SLU-PP-332 sound like the \u201clazy way out\u201d for people who want all the benefits of exercise with none of the effort, but it has a surprising range of research applications. SLU-PP-332 might, in the future, help people who <\/span>can\u2019t <\/span><\/i>exercise due to physical limitations or who are recovering from serious physical injuries \u2014 but also type 2 diabetics and people suffering from obesity.\u00a0<\/span><\/p>\n SLU-PP-332 pretty much remains a newborn in the grand scheme of things; the first research paper \u2014 which studied its effects on mice \u2014 was only published in the early 2020s. You\u2019d be forgiven for thinking that means further studies are limited, but that\u2019s not quite true. The landmark study was so exciting that researchers have jumped at the chance to discover what else SLU-PP-332 can do.\u00a0<\/span><\/p>\n That first study? It had astonishing results \u2014 and no, we\u2019re not overhyping that. Mice given SLU-PP-332 could suddenly run 70 percent longer and 50 percent further. Without previously exercising. Other performance boosters tend to be stimulants, but SLU-PP-332 doesn\u2019t rely on \u201ccheap tricks\u201d that lead to impressive but woefully transient results.<\/span><\/p>\n The initial research showed that the mice in the study underwent a total metabolic shift. They started burning fat (nearly exclusively!) while leaving carbs intact. They acquired the metabolic efficiency and physiological profile of mice subjected to grueling training regimens. Except <\/span>they weren\u2019t<\/span><\/i>. They were just given SLU-PP-332.\u00a0<\/span><\/p>\n What\u2019s more, the mice in that first study made new mitochondria (you know it, the \u201cpowerhouse of the cells\u201d and all that!) at much faster rates. That, in turn, makes muscles even more powerful. [1<\/a>]<\/span><\/p>\n Those findings alone are incredible. They make SLU-PP-332 an obvious compound to study in the context of metabolic syndrome, sarcopenia (age-related muscle loss), type 2 diabetes, and neuromuscular diseases (like MS and muscular dystrophy). Indeed, SLU-PP-332 studies devoted to all of these areas have already been conducted in the short time the compound has been around. [2<\/a>, 3<\/a>, 4<\/a>, 5<\/a>]<\/span><\/p>\n These directions of inquiry raise some interesting questions. Could the compound give people unable to exercise because they\u2019re too old, frail, or sick a helping hand as they struggle to hold onto muscle mass? Could the switch to fat metabolism that SLU-PP-332 forces, and its mitochondrial function boost, be part of new treatments for type 2 diabetes and obesity? Research that will answer these questions continues \u2014 but those aren\u2019t the only areas under active investigation!<\/span><\/p>\n Ready? Good, because many SLU-PP-332 studies go much further than the obvious (\u201cexercise in a bottle\u201d) \u2014 something that shows it to be a pretty versatile compound with a massive range of potential clinical applications.\u00a0<\/span><\/p>\n Studies have already identified SLU-PP-332 as a potential agent for patients with heart failure or at risk of it. The compound improves mitochondrial function and fatty acid metabolism, so that shouldn\u2019t be too surprising. [6<\/a>]<\/span><\/p>\n Ambitious researchers have raised the possibility that this same mechanism could be beneficial in treating neurological diseases \u2014 Alzheimer\u2019s and Parkinson\u2019s, perhaps, but also potentially schizophrenia, which is strongly associated with metabolic dysfunction. [7<\/a>] This line of inquiry is still in its very earliest stages, mind you, but it\u2019s too interesting not to mention.<\/span><\/p>\n Beyond that, SLU-PP-332 has been proposed as a treatment for COVID [8<\/a>], and even as a potential inhibitor of cancer cell growth [9<\/a>]. Does that make you go \u201cWow?\u201d You\u2019re not wrong \u2014 SLU-PP-332 is arguably one of <\/span>the<\/span><\/i> most interesting compounds to study right now.<\/span><\/p>\n Broad and vague, but true \u2014 SLU-PP-332 is <\/span>the<\/span><\/i> perfect research compound for anyone asking all the big questions about energy management at the cellular level. That includes, but definitely isn\u2019t limited to, researchers who investigate:<\/span><\/p>\n Dream of controlling metabolic pathways? SLU-PP-332 deserves a spot on your radar. And in your lab.<\/span><\/p>\n Dosing decisions depend on the model \u2014 and the goal of the study. Despite SLU-PP-332 being a fairly new compound, researchers have plenty of studies to review to aid their own designs.\u00a0<\/span><\/p>\n You might come across doses of 5 to 15 mg per kilogram of body weight for in vivo research, administered once a day. The protocol is different for in vitro research \u2014 there, doses of 1 \u00b5M to 10 \u00b5M are common. Even oral applications have been developed for the compound, although they\u2019re rarer.<\/span><\/p>\n But most begginer researches tend to use doses of 0.3-1mg per day.<\/p>\n Effects are dose-dependent, so determining the optimal protocol is always the first step. Once that\u2019s done, researchers also have to keep in mind that lyophilized SLU-PP-332 needs to be reconstituted to prepare it for research. Bacteriostatic water is the only sterile solvent suitable for the multi-dose design most studies use. It allows investigators to store the compound safely in the fridge and maximize the ROI they get from a single vial.\u00a0<\/span><\/p>\n That\u2019s done by injecting BAC water into the vial of dry SLU-PP-332 \u2014 for example, 1 mL for a 5 mg vial. Take it slow, and angle the needle at the vial wall. Swirl or roll until the solution becomes clear. No shaking, because that can upset and denature the compound.<\/span><\/p>\n Use our peptide dosage calculator<\/a> in order to find out the correct dose for your model.<\/p>\n SLU-PP-332<\/strong> er ikke et peptid \u2014 og selvom det retter sig mod \u201c\u00f8strogenrelaterede receptorer,\u201d har det heller ikke noget med \u00f8strogen at g\u00f8re. S\u00e5 hvad er det? SLU-PP-332 er dybest set en genvej til den energieffektive tilstand, som opslidende udholdenhedstr\u00e6ning normalt fremkalder.\u00a0<\/span><\/p>\n Denne lavmolekyl\u00e6re forbindelse aktiverer \u201cfor\u00e6ldrel\u00f8se\u201d nukleare receptorer kaldet ERR'er p\u00e5 trods af ikke at binde sig til \u00f8strogen. Pr\u00e6cis hvordan disse receptorer fungerer? Det er faktisk stadig lidt af et mysterium, men forskerne er enige om \u00e9n ting \u2013 de er l\u00e5se p\u00e5 udkig efter en n\u00f8gle. SLU-PP-332 g\u00f8r det arbejde. N\u00e5r den drejer den n\u00f8gle, skubber den kroppen ind i en af de mest gavnlige tilstande, den har adgang til.\u00a0<\/span><\/p>\n Pr\u00e6klinisk forskning peger p\u00e5 mere effektiv fedtforbr\u00e6nding og dramatisk forbedret udholdenhed<\/strong>. Hvad mere er, er SLU-PP-332 en direkte vej til den form for skift i muskelfibersammens\u00e6tning (mod den tr\u00e6thedsbestandige type!), som normalt kun er tilg\u00e6ngelig for seri\u00f8se atleter. Hvad betyder det helt kort? SLU-PP-332 signalerer til din kropp om at blive en slank, effektiv, energiforbr\u00e6ndende maskine. Ogs\u00e5 selvom du ikke l\u00f8ber en eneste mile og aldrig s\u00e6tter dig op p\u00e5 en cykel.\u00a0<\/span><\/p>\n Det er ret sp\u00e6ndende \u2013 og det g\u00f8r SLU-PP-332 til en interessant forbindelse for alle, der forsker i stofskifte, fedme, type 2-diabetes og aktivering af tr\u00e6ningseffekterne uden rent faktisk at motionere.<\/span><\/p>","protected":false},"featured_media":3443,"template":"","meta":{"_acf_changed":false,"ub_ctt_via":""},"product_brand":[],"product_cat":[52,46,45,44,51],"product_tag":[],"class_list":["post-3442","product","type-product","status-publish","has-post-thumbnail","product_cat-anti-inflammatory-response-research-peptides","product_cat-peptides-for-longevity-research","product_cat-peptides-for-fat-metabolism-research","product_cat-peptides-for-muscle-growth-research","product_cat-peptides-for-weight-management-research","first","instock","shipping-taxable","purchasable","product-type-simple"],"acf":[],"yoast_head":"\n\n
What Is SLU-PP-332, and What Makes This Compound Interesting for Research?<\/b><\/h2>\n
The Most Exciting SLU-PP-332 Research So Far \u2014 and a Glimpse of What\u2019s to Come<\/b><\/h2>\n
SLU-PP-332 Supercharges Endurance (and That\u2019s Not an Understatement)<\/b><\/h3>\n
SLU-PP-332 and Metabolic and Muscle-Loss Research\u00a0<\/b><\/h3>\n
New Areas of Study: SLU-PP-332 for Heart Failure, Neurological Diseases, and More<\/b><\/h3>\n
Who Might Consider Researching SLU-PP-332?<\/b><\/h2>\n
\n
Common Dosing Protocols for SLU-PP-332 Researched In-Vitro Models<\/b><\/h2>\n
Scientific References<\/b><\/em><\/h2>\n
\n